VDPHL01, the oral minoxidil designed for hair loss: what it is and how it differs from off-label minoxidil
VDPHL01 is an extended-release oral minoxidil being developed specifically for male pattern hair loss. Preliminary phase 3 data look favourable, but it is not authorised or sold in Spain. Here we explain what is known about it and how it differs from the oral minoxidil currently prescribed off-label.

Short answer
VDPHL01 is an extended-release oral minoxidil that Veradermics is developing specifically for male pattern hair loss. It is not authorised by the AEMPS or the EMA and is not available in Spain. In its phase 3 trial of 536 men, it outperformed placebo at 6 months, according to preliminary company data. In Spain today, oral minoxidil for hair loss is used off-label, with a prescription and a medical assessment.
Key points
- According to Veradermics' press release on study 304 (536 men), non-vellus hair increased by 28.6 hairs/cm² with once-daily dosing and by 36.4 with twice-daily dosing, compared with 6.6 on placebo, at 6 months.
- According to the summary of product characteristics on CIMA (AEMPS), Loniten 10 mg is the only oral minoxidil marketed in Spain, and it is indicated for high blood pressure, not hair loss.
- In the Vañó-Galván study (JAAD 2021) of 1,404 patients, the most common side effect of low-dose oral minoxidil was hypertrichosis (15.1%), and there were no life-threatening effects.
- In the trial by Penha et al. (JAMA Dermatology 2024) of 90 men, 5 mg of oral minoxidil a day did not outperform 5% topical minoxidil at 24 weeks.
VDPHL01 versus off-label oral minoxidil in Spain
The data come from different types of sources, and no trial has compared the two options directly.
| Aspect | VDPHL01 | Off-label oral minoxidil |
|---|---|---|
| Status in Spain | Not authorised by the AEMPS or EMA; not available | Loniten 10 mg marketed, authorised for high blood pressure |
| Indication for hair loss | In development; FDA application planned but not confirmed | No; off-label use with a prescription |
| Formulation | Extended release using a gel matrix | Split tablet or compounded (extemporaneous) preparation |
| Population studied | Men only, with mild or moderate hair loss | Case series of men and women (68% women in Vañó-Galván) |
| Safety data available | Preliminary company data, not peer-reviewed | Retrospective study of 1,404 patients published in JAAD |
VDPHL01 is an extended-release oral minoxidil formulation that the US company Veradermics is developing specifically for male pattern hair loss. It is not authorised by the AEMPS (the Spanish Agency of Medicines and Medical Devices) or the EMA, there is no known application to the European agency, and it cannot be obtained in Spain. The difference from the oral minoxidil already used for hair loss is that VDPHL01 has been studied for this indication and is going through the approval process for it. The oral minoxidil in use today is prescribed off-label, because it is authorised for high blood pressure.
What VDPHL01 is and why people are talking about it
Minoxidil started life as a blood pressure medicine, and its effect on hair was discovered almost by chance. Since then it has been used as a scalp lotion and, increasingly, as low-dose tablets. The problem is that no oral minoxidil is authorised for hair loss. Anyone taking it for their hair is using a drug designed for blood pressure, with the dose adjusted.
VDPHL01 aims to change that. It is Veradermics' own formulation (the company is listed on the New York Stock Exchange as MANE), and it uses a gel matrix to release minoxidil steadily over time. According to the company, this avoids the peaks in blood concentration that may be behind some unwanted effects. This is a design hypothesis put forward by the company. It has not been independently demonstrated.
What the phase 3 data from study 304 show
On 19 October 2026 the company announced the results of study 304, registered as NCT06972264. It is a randomised, double-blind, placebo-controlled phase 3 trial of 536 men with mild or moderate male pattern hair loss. They were split into three groups: 8.5 mg once daily, 8.5 mg twice daily, and placebo.
- With once-daily dosing, the count of non-vellus hairs in the target area rose by 28.6 hairs/cm² at 6 months.
- With twice-daily dosing, the increase was 36.4 hairs/cm².
- With placebo, the increase was 6.6 hairs/cm².
- According to the company, both doses beat placebo on the primary endpoints, with p<0.0001.
On safety, the company describes the drug as generally well tolerated, with no serious treatment-related adverse events and no cardiac events. Across study 304 and an earlier study, 302, more than 1,000 men received VDPHL01 or placebo. Veradermics planned to apply to the US Food and Drug Administration in 2026, but there is no confirmation that it has done so.
Three caveats matter here. First, these are preliminary data released by the company itself, in a press release and in its filing with the US securities regulator. They are not a peer-reviewed paper. Second, the absence of reported cardiac events does not mean they cannot occur. It means none appeared, or none were reported, in that analysis. Third, every participant was male, so we cannot assume it works the same way in women.
How oral minoxidil is used for hair loss in Spain today
According to the summary of product characteristics published on CIMA (the AEMPS medicines database), the only oral minoxidil marketed in Spain is Pfizer's Loniten 10 mg tablets. It is indicated for high blood pressure, starting at 5 mg a day, with a maximum of 100 mg a day. Hair loss is not among its indications.
So when a dermatologist prescribes oral minoxidil for hair loss, it is off-label use. This is legal when the doctor can justify it and the patient has been informed. There are two ways to get the low doses used for hair: splitting Loniten tablets, or having a pharmacy make up a compounded (extemporaneous) preparation on prescription. The Spanish journal Actas Dermo-Sifiliográficas has warned that dosing errors can happen in this process. That is one of the gaps a product made specifically for hair loss would fill. If you want to know what each option costs, we cover it in the price of minoxidil in Spain, topical and oral.
What we know about the safety of low-dose oral minoxidil
The key study is by Vañó-Galván and colleagues, published in JAAD in 2021. It was a multicentre retrospective study of 1,404 patients (68% of them women) from 10 centres in 6 countries. These were the most common adverse effects:
- Hypertrichosis, meaning more hair on the face or body: 15.1%.
- Dizziness: 1.7%.
- Fluid retention: 1.3%.
- Tachycardia: 0.9%.
- Headache: 0.4%.
- Swelling around the eyes (periorbital oedema): 0.3%.
- Insomnia: 0.2%.
No life-threatening adverse effects were recorded. That does not mean low doses are free of side effects. They do have some, which is why a doctor checks each person's blood pressure, heart and current medicines beforehand. We explain this in more detail in our map of the real side effects of low-dose oral minoxidil.
Oral or topical? What the head-to-head trial found
The data do not support the idea that tablets always beat lotion. In the randomised trial by Penha and colleagues (JAMA Dermatology, 2024), which included 90 men, 5 mg of oral minoxidil a day was not superior to 5% topical minoxidil at 24 weeks. The only advantage for the oral form in the photographic analysis was at the crown: 24% more, with a confidence interval of 0 to 48% (p=0.04). There was no advantage at the front of the scalp.
On the oral form, 49% developed hypertrichosis and 14% had headaches. Only 68 of the 90 participants completed the study, which makes the conclusions less robust. We go into this in what trials comparing oral and topical minoxidil have found. Comparing these figures with those for VDPHL01 is not meaningful either. The studies measured different things with different doses and designs, and no trial has compared the two options directly.
What an oral minoxidil authorised for hair loss would really change
If VDPHL01 were approved, it would definitely bring three things: a formal indication for hair loss, a dose manufactured for that purpose so there is no need to split tablets or rely on a compounded preparation, and a body of phase 3 trial evidence. What we cannot say today is that it is more effective or safer than the low-dose oral minoxidil already in use, because nobody has compared them.
Women are the other big unknown. The phase 3 trial included only men, whereas much of the experience with off-label oral minoxidil comes from female patients, as the Vañó-Galván series shows. If this applies to you, you may want to read why hair loss in women is different and what options are available in Spain.
Key takeaways
VDPHL01 is a promising development, but for now it rests on preliminary company data in men only, and it is not authorised in Europe. It is not available in Spain, and the oral minoxidil used for hair loss is still off-label use that needs a medical assessment. What is available today is medical treatment for hair loss: an assessment first, a prescription from a registered doctor where appropriate, and ongoing follow-up. That is how we work at AiON. You can:
Sources
- Comunicado de Veradermics sobre el estudio 304 de VDPHL01 (Business Wire, 19-10-2026)
- SEC Form 8-K, exhibit 99.1, Veradermics (19-10-2026)
- ClinicalTrials.gov NCT06972264
- Ficha técnica de Loniten 10 mg, CIMA (AEMPS)
- Penha et al. Minoxidil oral frente a tópico en alopecia androgenética masculina. JAMA Dermatology 2024
The guide explains. The doctor decides.
Online assessment, prescription where appropriate and ongoing follow-up.
Frequently asked questions
- Can I buy VDPHL01 in Spain?
No. VDPHL01 is not authorised by the AEMPS or the EMA, and there is no known application to the European agency. The company planned to apply for authorisation in the United States in 2026, but there is no confirmation that it has done so.
- Which works better for hair loss, oral or topical minoxidil?
The trial that compared them directly did not find oral minoxidil to be superior. In the study by Penha et al. (2024), 5 mg of oral minoxidil a day did not outperform 5% topical minoxidil at 24 weeks, apart from an advantage at the crown in the photographic analysis. Oral minoxidil caused hypertrichosis in 49% of participants, so the right choice depends on the individual case.
- Does oral minoxidil work for women?
For VDPHL01 we don't know, because its phase 3 trial included only men. Low-dose oral minoxidil is used off-label in women, and 68% of the 1,404 patients in the Vañó-Galván safety study were women. Hair loss in women has its own particular features, so each case needs an individual assessment.
- Does low-dose oral minoxidil have side effects?
Yes, although they are mild in most cases. In the Vañó-Galván study the most common was hypertrichosis (15.1%), followed by dizziness (1.7%), fluid retention (1.3%) and tachycardia (0.9%). There were no life-threatening effects. That is why your blood pressure and medical history are checked beforehand.
- Where can I get oral minoxidil prescribed with medical follow-up without going to a clinic?
Oral minoxidil needs a doctor's prescription, and in Spain its use for hair loss is off-label. A registered doctor can prescribe it either face to face or by telemedicine, always after assessing your case first. You then need follow-up so the doctor can check how well it is working and look out for side effects.
Keep reading
How long hair loss treatment takes to work: what happens at 3, 6 and 12 months
You won't see results from hair loss treatment within a few weeks. Here's what the evidence shows at 3, 6 and 12 months, why you may shed more hair at first, and what happens if you stop.
ReadTreatments and medicinesMy hair loss treatment isn't working after 6 months: what to check before switching
Six months is the very end of the timeframes set out in the Spanish summaries of product characteristics, and finasteride's main aim is to stop hair loss, not to regrow a lot of hair. Before you switch treatment, check four things: how long you have been on it, how consistently you have used it, what you expected to achieve, and whether the diagnosis and the authorised indication fit your case.
ReadTreatments and medicinesFemale androgenetic alopecia: which treatments have evidence behind them and which is approved in Spain
In Spain, the only treatment approved specifically for female androgenetic alopecia is topical minoxidil 2%, and a Cochrane review backs it up. We explain what the trials show, what is known about the alternatives used off-label, and what a doctor looks at before suggesting treatment.
Read




